Innovation in Pharma

Various thesis topics in pharmaceutical innovation

Quality and Outcome of New Drug Appprovals

Pharmaceutical companies, such as Novartis or Roche, are among the top investors in research & development (R&D) worldwide. Over the last years, the industry launched 30-50 new drugs per years.
Scope of the thesis: In your project, you will analyse new drug launches over a period of 25 years (1999-2023). You will categorize the drug launches with respect to stakeholders (sponsor, originator), quality (drug modality, therapeutic indication, approval type) and outcome (prizing, worldwide sales) and try to describe the industry’s development in that time-period.

 

Pharma Innovation and Strategy

The global biopharmaceutical industry (biotech and pharma) invests around USD 200 billion in research and development (R&D) per year. Big pharma companies are among the global top investors in R&D – allocating up USD 10 billion per year in drug discovery and development.

Scope of the thesis: First, you will perform an annual company report analysis of the top 20 biopharmaceutical companies and analyse their key decisions and resource allocations in R&D for the past 10 years. In addition, you will use corporate communication and investor relation information to supplement your data basis. Second, you will use the information to understand the R&D strategies of top 20 pharma companies. Third, you will analyse the R&D output (new drug launches, commercial value of launches, market value). Fourth, you will evaluate which strategies were more successful.

 

Originator of Pharma Innovation

Big pharma companies leverage internal and external innovation to bring new drugs to market. Next to discovery research and technology providers as well as clinical research organization, companies, such as Roche and Pfizer, have licensed or acquired more than half of their product portfolios and R&D project pipelines from peers and biotech companies.

Scope of the thesis: In your project, you will analyse the current product portfolios and R&D pipelines of top 20 pharma companies and evaluate the sources of innovation (the originator of the drug compound). In doing so, you will analyse annual reports, patent information and other legally relevant information to make an industry portfolio analysis.

 

Economies of Scope in Pharma R&D

Pharmaceutical companies, such as Novartis or Roche, are among the top investors in research & development (R&D) worldwide. On average, they invest up to USD 10 billion annually to discover and develop new drugs/vaccines. Next to technologies or management processes, R&D strategy is a major differentiator in the market success of these research-driven companies.

Scope of the thesis: In your project, you will analyse the R&D strategies and focus points (therapeutic indications) of top 20 pharma companies for the last 20 years and try to correlate your finding/results with the corporate output (viz. number of new drugs launched) in that time-period.

 

Does Science Translate into Pharma Success?

Pharmaceutical companies, such as Novartis or Roche, are among the top investors in research & development (R&D) worldwide. On average, they invest up to USD 10 billion annually to discover and develop new drugs/medicines. Next to strategies or management process, science is a major differentiator in the market success of these research-driven companies.

Scope of the thesis: In your project, you will analyse the scientific performance of top 20 pharma companies for the last 20 years and try to correlate the results with the output (viz. number of new drugs launched) in that time-period.

 

Your profile:

  • Practical experience in managing and analysing big data sets
  • Organized, conscientious and result-oriented working attitude
  • Very good communication and written skills in English

 

What we offer:

  • Conduct research with high practical relevance and impact
  • Methodological support
  • Dynamic and interdisciplinary team
 
How to apply:
Please send your CV, transcripts, and a motivation letter to Naomi Haefner (naomi.haefner@unisg.ch) and Alexander Schuhmacher (alexander.schuhmacher@thi.de).
NHaefner
Prof. Dr. Naomi Haefner
Assistant Professor of Technology Management
AlexanderSchuhmacher
Dr. Alexander Schuhmacher
Research Fellow